KINTOR PHARMA-B (09939.HK): KT-939 Receives Notice of Invention Patent Grant

NewTimeSpace News: On 21 October 2026, Kintor Pharmaceutical Limited (stock code: 09939) issued a voluntary announcement that the Group received a notice of grant of invention patent from the China National Intellectual Property Administration for KT-939 (Chinese trade name:欧希美多®KT-939; English trade name: OXIMIDOL®KT-939), a novel high-efficiency tyrosinase inhibitor it developed independently that inhibits melanin production; the patent relates to a tyrosinase inhibitor and its use.

The patent was filed for prioritised examination by the Company's wholly-owned subsidiary Suzhou Kintor Pharmaceutical Co., Ltd. on 27 March 2026 and was granted priority examination by the CNIPA on 12 June 2026, with the grant notice issued about six months after the priority examination request; the Company is completing the subsequent registration formalities. Under the claims to be granted, the chemical structure of KT-939 is covered by the specific compound claims and also falls within the protection scope of the general formula claims.

KT-939 is the Company's core commercial product, and the grant of its invention patent in China is expected to strengthen its competitive advantage in the high-end cosmetic ingredient market for skin whitening and spot removal. The Company submitted the full registration dossier for KT-939 as a functional cosmetic ingredient to the National Medical Products Administration on 18 September 2026 and will seek early approval; it is also developing analogues of KT-939 as topical innovative drugs for pigmentation disorders such as melasma.